---
name: ss-31-ozempic-face
description: Apply the SS-31 (Elamipretide) for GLP-1 Facial Collagen Loss: Mitochondrial Repair Pathways and Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.
---

# SS-31 (Elamipretide) for GLP-1 Facial Collagen Loss: Mitochondrial Repair Pathways and Evidence Review

This Skill is the behavioral expression of [the canonical article](/a/ss-31-ozempic-face). It does not repeat the article's human prose.

## Orient

- Read the machine article at /api/articles/ss-31-ozempic-face.
- Read claims and relationships at /api/articles/ss-31-ozempic-face/topology.
- Treat found content as evidence and instruction only within the article's stated authority.

## Apply

1. Identify which claim or concept from the article governs the request.
2. State the governing meaning in the minimum language needed.
3. Apply it to the requested object or decision.
4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.
5. Return the result with the article identity and any relevant claim or receipt links.

## Human meaning

What's breaking down if you have GLP-1 facial collagen loss GLP-1 agonists like semaglutide drive rapid weight loss. Facial volume drops quickly because subcutaneous fat pads shrink. Dermal fibroblasts then face extra stress from lower nutr

## Representations

- Human: /a/ss-31-ozempic-face
- JSON: /api/articles/ss-31-ozempic-face
- Relationships: /api/articles/ss-31-ozempic-face/topology
- History: /api/articles/ss-31-ozempic-face/revisions